The skin autofluorescence may help to select patients with Type 2 diabetes candidates for screening to revascularization procedures

Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventiona...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology Vol. 23; no. 1; pp. 32 - 4
Main Authors: Alkhami, Fadi, Borderie, Gauthier, Foussard, Ninon, Larroumet, Alice, Blanco, Laurence, Barbet-Massin, Marie-Amélie, Ferriere, Amandine, Ducos, Claire, Mohammedi, Kamel, Fawaz, Sami, Couffinhal, Thierry, Rigalleau, Vincent
Format: Journal Article
Language:English
Published: London BioMed Central 13.01.2024
Springer Nature B.V
BMC
Subjects:
Advanced glycation end-products
Advanced glycosylation end products
Angiology
Arteries
Atherosclerosis
Cardiology
Cardiovascular disease
Cardiovascular diseases
Carotid arteries
Clinical trials
Cohort analysis
Comment
Coronary vessels
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - diagnosis
Foot diseases
Glycation End Products, Advanced
Health risks
Human health and pathology
Humans
Ischemia
Leg ulcers
Life Sciences
Medical prognosis
Medicine
Medicine & Public Health
Mortality
Myocardial ischemia
Population studies
Revascularization
Risk Factors
Skin
Skin autofluorescence
Smoking
Type 2 diabetes
Vein & artery diseases
Skin autofluorescence
Type 2 diabetes
Advanced glycation end-products
Revascularization
Advanced
Humans
Risk Factors
Type 2
Skin
Diabetes Mellitus
Glycation End Products
Smoking
ISSN:1475-2840, 1475-2840
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05–4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Correspondence-1
ObjectType-Commentary-3
content type line 23
ISSN:1475-2840
1475-2840
DOI:10.1186/s12933-024-02121-5